Randomized phase III clinical trials (RCTs) are critical in improving patient care and outcomes. In a typical RCT, an experimental therapy is compared with the current standard therapy. Positive results from well-designed and executed RCTs often establish new standards of care and form the basis of regulatory approval of new drugs. Approximately 80% of initial approvals for new oncology drugs by the US Food and Drug Administration from 1998 through 2008 were based primarily on positive results from RCTs (1). However, many RCTs do not show that experimental therapies are statistically significantly superior to standard therapies, thus raising the question of whether poor trial design is a contributing factor.
Randomized phase III clinical trials (RCTs) are critical in improving patient care and outcomes. In a typical RCT, an experimental therapy is compared with the current standard therapy. Positive results from well-designed and executed RCTs often establish new standards of care and form the basis of regulatory approval of new drugs. Approximately 80% of initial approvals for new oncology drugs by the US Food and Drug Administration from 1998 through 2008 were based primarily on positive results from RCTs (1) . However, many RCTs do not show that experimental therapies are statistically significantly superior to standard therapies, thus raising the question of whether poor trial design is a contributing factor.
A key factor to consider in designing an RCT is the magnitude of the expected benefit (d) of the experimental therapy over the standard therapy. Together with Type I error (a) and power (1 2 b), d determines the number of patients to be enrolled and the number of person-years of follow-up in a RCT. A larger d means fewer patients are required and trials can be completed more quickly. However, if d is set unrealistically high, the trial will be underpowered to detect a smaller but still clinically meaningful benefit, resulting in a negative trial. In contrast, a smaller d requires more patients, costs more money and time, and may detect statistically significant benefits that are not clinically meaningful (2, 3) .
The high percentage of "negative" RCTs suggests that investigators frequently use overly optimistic assumptions of d. A recent review of 18 "positive" RCTs, which formed the basis for US Food and Drug Administration approval of new oncology drugs, revealed that the observed benefit (B) was less than d in 38% of the RCTs investigated (2) . This finding led the authors to question whether regulatory approval is warranted when outcomes of trials are statistically significant but observed Bs are less than predefined ds. To evaluate how closely d approximates B in RCTs evaluating treatments for cancer, we conducted a systematic review of RCTs evaluating systemic therapy in adult cancer patients. We also 
Background
In designing phase III randomized clinical trials (RCTs), the expected magnitude of the benefit of the experimental therapy (d) determines the number of patients required and the number of person-years of follow-up. We conducted a systematic review to evaluate how reliably d approximates the observed benefit (B) in RCTs that evaluated cancer treatment.
Methods
RCTs evaluating systemic therapy in adult cancer patients published in 10 journals from January 1, 2005, through December 31, 2009, were identified. Data were extracted from each publication independently by two investigators. The related-samples Sign test was used to determine whether the median difference between d and B was statistically significant in different study subsets and was two-sided.
Results
A total of 253 RCTs met the eligibility criteria and were included in the analysis. Regardless of whether benefit was defined as proportional change (median difference between d and B = 213.0%, 95% confidence interval [CI] = 221.0% to 28.0%), absolute change (median difference between d and B = 28.0%, 95% CI = 29.9% to 25.1%), or median increase in a time-to-event endpoint (median difference between d and B = 21.4 months, 95% CI = 22.1 to 20.8 months), d was consistently and statistically significantly larger than B (P < .001, for each, respectively). This relationship between d and B was independent of year of publication, industry funding, management by cooperative trial groups, type of control arm, type of experimental arm, disease site, adjuvant treatment, or treatment for advanced disease, and likely contributed to the high proportion of negative RCTs (158 [62.5%] of 253 studies).
Data Collection
Data of interest were extracted independently from each publication by two investigators (B. You and H. K. Gan). Discrepancies were resolved by consensus or adjudication by a third investigator (G. R. Pond). General characteristics were extracted, including publication year, tumor type, treatment setting (ie, adjuvant or for advanced disease), any funding by pharmaceutical companies, cooperative groups conducting the study, institutional affiliation of the first author, number of treatment arms, type of control arm, type of experimental arm and use of blinding, and analysis by intention-to-treat population and method of analysis. Characteristics of the statistical design were extracted, including the primary endpoint (when stated explicitly or based implicitly on the basis of the sample size calculation), d, a, b, and use of interim analyses. When the publication reported on intratrial changes to design variables (eg, protocol amendment to sample size), the data presented in the publication were assumed to be based on the final amendment. Statistical outcome data, including B and the associated P value (or an estimate of precision such as a 95% confidence interval [CI]), were also collected from the RCTs. If not stated explicitly, B was obtained by subtracting the outcome of standard therapy from that of the experimental therapy. Depending on the publication, d and B were extracted as the proportional change in a hazard ratio (eg, 25% benefit for hazard ratio = 0.75), absolute change (eg, increase in 1-year survival = 20%), or a median increase in a time-to-event primary endpoint (eg, increase in median survival = 2 months).
A study was considered to be positive if the experimental therapy (or an experimental arm in RCTs with more than two arms) was
CONTEXTS AND CAVEATS

Prior knowledge
Positive results from randomized phase III clinical trials (RCTs) of cancer therapies are used to establish new standards of care. However, many RCTs do not show that experimental therapies are better than standard therapies, and this may be the result of poor trial design. The high proportion of negative RCTs also suggests that investigators may often use overly optimistic assumptions regarding the magnitude of the expected benefit (d) of the treatment. 
Study design
Contribution
Investigators assumptions of d were often greater than B, and this relationship was independent of disease type, treatment setting, industry funding, cooperative group, or experimental treatment type.
Implication
When designing RCTs, investigators frequently use overly optimistic assumptions of treatment benefits, likely contributing to the high percentage of negative RCTs.
Limitation
As only published RCTs were included in the analysis, there is the potential for publication bias as negative studies are less often published. between d and B was assessed in scatter plots, and the strength of the association was tested using the Spearman r. The median values of d and B were also compared across groups with different statistically superior to the standard therapy (B > 0 and P < a, or a CI excluding 0). All other studies were considered negative.
From the Editors
Statistical Analysis
Descriptive statistics (mean, median, and range) were collected as appropriate to summarize trial characteristics as well as expected and observed statistical outcomes. The difference between the observed and the expected benefit (B 2 d) in a study is represented by Ŷ. A negative value for Ŷ indicates that the observed benefit was less than expected, whereas a positive Ŷ indicates that the observed benefit was greater than expected. The related-samples Sign test was used to determine whether Ŷ was statistically significantly different from 0 in different study subsets. The relationship * Country of origin was assigned on the basis of the location of the institution at which the first author was affiliated. trial outcomes (statistically significant detriment, non-statistically significant detriment, non-statistically significant benefit, and statistically significant benefit) using the Kruskal-Wallis test with post hoc Mann-Whitney testing. Differences in the frequency of characteristics in these groups were also examined using x 2 analysis or Fisher exact test. All tests were two-sided, and a P value of less than .05 was considered statistically significant. No corrections were applied for multiple significance testing.
Results
From an initial 1135 studies identified by MEDLINE or manual search, 315 RCTs met the study inclusion criteria. There was sufficient information to allow a full analysis of 253 RCTs (80.3%) (Figure 1 ). The most common cancer types were breast, thoracic, colorectal, and other gastrointestinal cancers (Table 1) . Of these 253 RCTs meeting inclusion criteria, 135 (53.4%) were conducted in the first-line metastatic setting and 68 (26.9%) in the adjuvant setting. In 202 (79.8%) of the 253 studies, the experimental therapy was compared with an active therapy, and the remainder were compared with supportive care or placebo. The most common design was a two-arm study (224 of 253 studies, 88.5%), with a time-to-event outcome as the primary endpoint Table 2) .
Of these 253 studies, 95 (37.5%) were considered positive studies and 158 (62.5%) were negative studies. Among these negative studies, a trend toward benefit (B > 0 but P > a) was observed in 108 studies, a trend toward detriment (B < 0 but P > a) was observed in 42 studies, and a statistically significant detriment (B < 0 and P < a) was observed in eight studies. These select 158 negative studies enrolled a total of 100 275 patients, with the subset of eight studies with statistically significant detriment enrolling 5287 patients.
Regardless of whether benefit was defined as proportional change, absolute change, or median increase in a time-to-event endpoint, d was consistently and statistically significantly larger than B as indicated by Ŷ values of 213.0% (95% CI = 221.0% to 28.0%, P < .001), 28.0% (95% CI = 29.9% to 25.1%, P < .001), and 21.4 months (95% CI = 22.1 to 20.8 months, P < .001), respectively (Table 3 ). In 81.0% of RCTs, the data points are below the line of unity, indicating that B is less than d in these RCTs. The association between d and B is either nonexistent (P = .98 or .43) (Figures 2, A and C, respectively) or very weak (r = 0.26, P = .006) (Figure 2, B) . Subset analyses on the basis of publication year, presence of industry funding, management by cooperative * P values were calculated by the related-samples Sign test and were two-sided. NA = not available because only one relevant study was identified. † Indicates the P value is not statistically significant, however, the total number of studies is no more than 11.
trial groups, type of control or experimental arm, disease site, and treatment setting showed that these findings held true across all subgroups examined (Table 3 ). The magnitude of d was not associated with the likelihood of positive studies. In an exploratory analysis, the frequency of positive studies is not statistically significantly higher in the lowest quartile of studies, on the basis of the absolute value of d, compared with the remaining three-quarters of studies (43.8% vs 35.6%, P = .41). Similarly, the frequency of studies with detrimental outcomes (both trend or statistically significant) does not vary by this same subgrouping (20.8% vs 20.0%, P = .84). Based on study outcome (statistically significant detriment, non-statistically significant detriment, non-statistically significant benefit, and statistically significant benefit), the median value of d does not differ substantially among these groups (Figure 3, A-C) . Although positive studies achieve higher values of B compared with other groups, there is a substantial overlap between B values of the group with a nonstatistically significant benefit and the group with a statistically significant benefit (Figure 3, D-F) . Two studies in the nonstatistically significant benefit group have B values that are greater than any of the studies in the statistically significant benefit group (Figure 3, F) . Overall, 57 (52.8%) of 108 studies in the group with non-statistically significant benefit have B values that overlapped with those in the statistically significant benefit group. Relationship between the expected benefit and the observed benefit for studies (n = 253) included in the systematic review. A) Proportional change, B) absolute change, and C) absolute increase in time to event (in months) were investigated. The solid line is the line of unity, which represents perfect concordance between the expected and observed benefits. The red dashed line indicates the zero point on the y-axis; studies with observed benefits below this line are those in which experimental therapies have worse outcomes compared with standard therapies. Solid red, empty blue, and solid black circles represent studies in which a statistically significant detriment, non-statistically significant difference, and statistically significant benefit, respectively, were observed. (A and D) ; as an absolute change in the middle column (B and E); and as an absolute improvement in time to event (months) in the right column (C and F) . The values beside each bar indicate the median value group. Circles represent outliers defined as having a distance of 1.5-3.0 box lengths from the superior or inferior margin of the box, and asterisks represent extreme values, which were a distance greater than 3 box lengths from the superior or inferior margin of the box. Dagger indicates P < .05 compared with studies in which a statistically significant benefit was found. Double dagger indicates P < .05 compared with studies with non-statistically significant benefit. Section mark indicates P < .05 compared with studies with a non-statistically significant detriment. All P values were two-sided and calculated using Kruskal-Wallis test with post hoc Mann-Whitney testing.
Other characteristics of studies in the four outcome groups are presented in Table 4 . The only factor associated with trial outcome was the presence of industry funding. Trials with industry funding were more likely to be positive compared with those in which industry funding was absent or unknown (42.6% vs 28.8% vs 25.0%, respectively, P = .01). Studies with industry funding were also associated with a small but statistically significant increased risk of detriment in the experimental arm (increased risk of detriment = 4.9%, 0%, and 0% for RCTs with industry funding, without industry funding, and unknown, respectively; P = .01). Studies evaluating targeted agents did not have a higher likelihood of being positive.
Discussion
Several investigators have recently reviewed RCTs that led to approval of new agents by the US Food and Drug Administration. They provided valuable commentary about how oncology RCTs should be interpreted for both clinical and statistical significance, thereby ensuring efficient, ethical, and economical drug development (2,3). However, as few investigators would initiate a trial if they did not think it had a reasonable chance of showing a statistically significant and clinically meaningful benefit, it could be argued that the real problem is in how (in)accurate the assumptions about d are that led to the decision to initiate a trial. In our review of 253 oncology RCTs conducted in the modern post-CONSORT era, the d was greater than B in as many as 81.0% of RCTs. On average, investigators' assumptions of d were two to three times that of the eventual B. No subsets of RCTs on the basis of disease type, treatment setting, industry funding, cooperative group, or experimental treatment type were spared from this problem.
The magnitude of d was also a poor predictor of whether a trial would be positive, even using a relatively conservative definition of a positive trial without considering whether the level of benefit is clinically meaningful or not (B > 0 and P < a or CI excluding 0). The human and financial costs of this problem are extreme. Using a conservative cost estimate of US $62 million per RCT (4), the cost of the 158 negative RCTs in this review is US $10 billion. Furthermore, 100 275 patients were enrolled in these RCTs, including 5287 patients enrolled in eight RCTs in which the experimental treatment was statistically significantly detrimental. Such a high rate of negative RCTs was disappointing given that most of these RCTs would have only been initiated because of promising phase I/II results. This relatively high percentage of negative studies and possible harm may discourage oncologists and patients from participating in future RCTs.
At present, the derivation of d at the time of study inception is usually an empirical process based on limited data from early phase trials and/or investigators' experience. We (5) and others (6) have previously documented some of the problems with this approach. Promising results from phase I/II studies are reproduced infrequently in phase III RCTs in which there is less patient selection bias and possibly a more rigorous design and analysis. More research is required to determine how to better define d. One approach is to derive d using statistical modeling rather through empiricism, but this approach will require greater access to and validation of such models (7). In the interim, more frequent use of interim analyses or certain adaptive trial designs may help to address the problem of unreliable d values. The use of interim analyses was described in only 39.9% of the studies in this review, suggesting that they are either underused or underreported. Interim analyses offer the option of early study termination if the interim estimate of B suggests futility or detriment. Alternately, when the interim B achieves an a priori specified level of efficacy, early study termination is again possible as long as appropriate methodological rigor, and high reporting standards are maintained to avoid the potential pitfalls of early termination (8, 9) . The use of adaptive trials designs, although still relatively infrequent, offers potential advantages. Adaptive trial designs prospectively define potential intrastudy modifications of trial methodology, such as modification of sample size based on interim data. This may be particularly relevant because up to 50% of RCTs that do not show a statistically significant benefit might actually be falsenegative trials. It is possible that these studies did not enroll enough patients and are underpowered because of unreliable d values, particularly those studies with large B. Adaptive designs would allow mid-study adjustment of study power when the interim B is clinically encouraging, but statistical significance is unlikely to be achieved (10, 11) .
The substantial overlap in B between RCTs with a statistically significant benefit and non-statistically significant benefit could also result from some overpowered studies that detect differences that are not clinically meaningful. This hypothesis is supported by our data which showed that many positive studies were statistically significant despite B being less than d. Echoing the concerns of Ocana and Tannock (2), it is unclear whether these positive studies should warrant regulatory approval in the absence of other positive supporting data.
Finally, our findings highlight the importance of better characterization of patients based on tumor biology rather than morphology alone (12) (13) (14) . To decrease the number of patients required and the cost of conducting RCTs, improvements in the methods for identifying those patients who are likely to benefit from therapy are needed and could change the current practice of conducting large studies in unselected patients to detect small benefits (15) .
This study has several limitations. Only published RCTs were included in our analysis. Negative studies or studies with therapeutically adverse outcomes are less likely to be published (16, 17) and hence would be underrepresented in our review. Therefore, our findings likely understate the degree to which investigators used overly optimistic assumptions of d in planning trials. It is also possible that the published data may not accurately reflect the design parameters of the original study protocols. As such, we heartily endorse the recent decision by the Journal of Clinical Oncology to mandate that the entire statistical section of phase II/III trial protocols be made available at the time of publication (18) . Last, 38 RCTs were excluded from our study because of insufficient data in sample size estimation or planned sample size. Although it is unlikely that inclusion of these studies will alter our results, this finding emphasizes the importance of enforcing CONSORT reporting requirements during the article review process.
In conclusion, investigators consistently use overly optimistic assumptions of treatment benefits when designing RCTs to evaluate treatments for cancer, likely contributing to the high percentage of negative RCTs. Attempts to reduce the frequency of negative RCTs should focus on better ways of specifying the expected benefit. More frequent use of interim analyses, adaptive designs, and better patient selection are possible ways of mitigating this problem.
